Cresset Asset Management LLC Trims Stock Holdings in United Therapeutics Corporation $UTHR

Cresset Asset Management LLC lowered its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 37.3% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 5,445 shares of the biotechnology company’s stock after selling 3,242 shares during the quarter. Cresset Asset Management LLC’s holdings in United Therapeutics were worth $1,565,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of UTHR. US Bancorp DE lifted its holdings in shares of United Therapeutics by 12.2% during the first quarter. US Bancorp DE now owns 1,971 shares of the biotechnology company’s stock worth $608,000 after purchasing an additional 215 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its stake in United Therapeutics by 48.6% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 21,590 shares of the biotechnology company’s stock valued at $6,656,000 after acquiring an additional 7,058 shares during the period. Invesco Ltd. boosted its holdings in shares of United Therapeutics by 46.1% in the 1st quarter. Invesco Ltd. now owns 465,115 shares of the biotechnology company’s stock valued at $143,381,000 after acquiring an additional 146,664 shares during the last quarter. Nuveen LLC acquired a new stake in shares of United Therapeutics in the first quarter worth $83,533,000. Finally, HighTower Advisors LLC raised its holdings in shares of United Therapeutics by 8.1% during the first quarter. HighTower Advisors LLC now owns 20,362 shares of the biotechnology company’s stock worth $6,277,000 after purchasing an additional 1,530 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 21,000 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $478.60, for a total transaction of $10,050,600.00. Following the completion of the sale, the chief financial officer owned 8,142 shares of the company’s stock, valued at $3,896,761.20. The trade was a 72.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $478.58, for a total transaction of $10,768,050.00. The SEC filing for this sale provides additional information. Insiders sold a total of 619,300 shares of company stock worth $277,383,609 in the last quarter. 10.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

UTHR has been the topic of several recent research reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a report on Monday. UBS Group boosted their price objective on United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Cantor Fitzgerald upped their target price on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. Oppenheimer raised their target price on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Finally, HC Wainwright boosted their price target on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Stock Down 0.7%

Shares of United Therapeutics stock opened at $476.36 on Wednesday. The firm has a market cap of $20.51 billion, a PE ratio of 18.05, a P/E/G ratio of 4.76 and a beta of 0.86. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $492.62. The business has a 50-day moving average price of $455.16 and a 200 day moving average price of $371.12.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating the consensus estimate of $6.89 by $0.27. The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.United Therapeutics’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period last year, the company earned $6.39 earnings per share. On average, sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.